Patten Group Inc. lowered its stake in shares of Astrazeneca Plc (NYSE:AZN – Free Report) by 54.0% during the first quarter, Holdings Channel reports. The fund owned 30,089 shares of the company’s stock after selling 35,317 shares during the period. Astrazeneca makes up approximately 1.0% of Patten Group Inc.’s holdings, making the stock its 15th biggest holding. Patten Group Inc.’s holdings in Astrazeneca were worth $5,877,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Triumph Capital Management acquired a new position in shares of Astrazeneca during the third quarter worth approximately $25,000. MV Capital Management Inc. bought a new stake in shares of Astrazeneca during the fourth quarter valued at approximately $26,000. Bangor Savings Bank increased its holdings in shares of Astrazeneca by 102.7% in the fourth quarter. Bangor Savings Bank now owns 304 shares of the company’s stock valued at $28,000 after purchasing an additional 154 shares in the last quarter. Eagle Bay Advisors LLC acquired a new stake in shares of Astrazeneca in the fourth quarter valued at approximately $30,000. Finally, YANKCOM Partnership bought a new position in Astrazeneca in the 4th quarter worth approximately $31,000. Institutional investors and hedge funds own 20.35% of the company’s stock.
Astrazeneca News Summary
Here are the key news stories impacting Astrazeneca this week:
- Positive Sentiment: AstraZeneca announced a strategic collaboration with Abbisko Therapeutics to advance a Phase I/II clinical trial of lumipodlin (ABSK043) combined with Tagrisso for non-small cell lung cancer, adding another pipeline development opportunity. Article Title
- Positive Sentiment: AZN’s cancer drug Enhertu won another EU approval for HER2-positive solid tumors, extending its commercial footprint and reinforcing investor confidence in the company’s oncology franchise. Article Title
- Positive Sentiment: Goldman Sachs and Bank of America both reaffirmed “buy” ratings on AstraZeneca, while Erste Group raised its FY2026 EPS estimate, signaling continued analyst confidence in earnings power. Article Title
- Positive Sentiment: Separate style-score coverage from Zacks highlighted AZN as both a strong value stock and a strong momentum stock, which may have supported buying interest. Article Title
- Neutral Sentiment: MarketBeat noted that AstraZeneca’s shares have recently traded below some valuation-based fair value estimates, suggesting the stock still screens as expensive despite the recent rally.
Astrazeneca Price Performance
Astrazeneca (NYSE:AZN – Get Free Report) last issued its earnings results on Wednesday, April 29th. The company reported $2.58 EPS for the quarter, beating the consensus estimate of $2.52 by $0.06. The company had revenue of $15.29 billion during the quarter, compared to analysts’ expectations of $14.93 billion. Astrazeneca had a net margin of 17.19% and a return on equity of 30.86%. As a group, analysts forecast that Astrazeneca Plc will post 10.28 EPS for the current year.
Analysts Set New Price Targets
Several research analysts have issued reports on AZN shares. DZ Bank raised Astrazeneca from a “neutral” rating to a “buy” rating in a report on Wednesday, April 29th. Bank of America restated a “buy” rating on shares of Astrazeneca in a research report on Wednesday. Weiss Ratings lowered Astrazeneca from a “buy (b)” rating to a “buy (b-)” rating in a research note on Thursday, June 18th. TD Cowen reiterated a “buy” rating on shares of Astrazeneca in a report on Wednesday, March 18th. Finally, Jefferies Financial Group reiterated a “buy” rating on shares of Astrazeneca in a research report on Friday, June 26th. Fourteen equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $205.33.
Check Out Our Latest Research Report on Astrazeneca
Astrazeneca Company Profile
AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.
The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.
Featured Stories
- Five stocks we like better than Astrazeneca
- Shorting the Grid: Bloom Energy’s $25B AI Power Play
- SanDisk’s Volatility May Be Telling Bulls What They Want to Hear
- Meta’s AI Compute Push Could Turn Its Massive CapEx Bill Into a Competitive Weapon
- 3 Dividend ETFs Built for Stability in a Volatile Market
Want to see what other hedge funds are holding AZN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Astrazeneca Plc (NYSE:AZN – Free Report).
Receive News & Ratings for Astrazeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astrazeneca and related companies with MarketBeat.com's FREE daily email newsletter.
